N3-(2-(2-fluoropyridin-4-yl)pyrido[3,4-d]pyrimidin-4-yl)-N1,N1,3-trimethylbutane-1,3-diamine

ID: ALA4461790

PubChem CID: 135390229

Max Phase: Preclinical

Molecular Formula: C19H23FN6

Molecular Weight: 354.43

Molecule Type: Unknown

Associated Items:

This compound is not in our inventory system

Names and Identifiers

Canonical SMILES:  CN(C)CCC(C)(C)Nc1nc(-c2ccnc(F)c2)nc2cnccc12

Standard InChI:  InChI=1S/C19H23FN6/c1-19(2,7-10-26(3)4)25-18-14-6-8-21-12-15(14)23-17(24-18)13-5-9-22-16(20)11-13/h5-6,8-9,11-12H,7,10H2,1-4H3,(H,23,24,25)

Standard InChI Key:  FRLQLTXVVWDXLN-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 26 28  0  0  0  0  0  0  0  0999 V2000
   16.6616   -2.3278    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.0743   -3.0376    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.4828   -2.3253    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.7884   -3.4504    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   18.5086   -7.1941    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.9210   -5.9282    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.1850   -4.6916    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.9210   -4.2795    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.0660   -4.6916    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   17.8021   -5.9282    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.8021   -6.7819    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.6235   -4.6916    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   18.5071   -5.5133    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.1850   -5.5160    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   16.3594   -5.9282    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   16.3606   -3.4537    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   19.2438   -5.9205    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.0660   -5.5160    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.6235   -5.5160    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.2447   -6.7819    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   16.3594   -4.2795    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   18.5143   -3.0420    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.2174   -3.4585    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   19.2083   -4.2756    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.9296   -3.0578    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   18.5014   -8.0113    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  1  0
  3  2  1  0
 18  9  2  0
  4 22  1  0
  6 14  2  0
 17 20  2  0
 15 19  2  0
 18 10  1  0
 12 21  2  0
 19 12  1  0
 18 15  1  0
  7 14  1  0
 21 16  1  0
 10 11  1  0
  5 20  1  0
 11  5  2  0
 21  9  1  0
 13 17  1  0
  8  7  2  0
 19  6  1  0
 16  2  1  0
  2  4  1  0
 12  8  1  0
 13 10  2  0
 22 23  1  0
 23 24  1  0
 23 25  1  0
  5 26  1  0
M  END

Alternative Forms

  1. Parent:

    ALA4461790

    ---

Associated Targets(Human)

LATS1 Tchem Serine/threonine-protein kinase LATS1 (877 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
LATS2 Tchem Serine/threonine-protein kinase LATS (902 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 354.43Molecular Weight (Monoisotopic): 354.1968AlogP: 3.37#Rotatable Bonds: 6
Polar Surface Area: 66.83Molecular Species: BASEHBA: 6HBD: 1
#RO5 Violations: HBA (Lipinski): 6HBD (Lipinski): 1#RO5 Violations (Lipinski):
CX Acidic pKa: CX Basic pKa: 9.35CX LogP: 2.69CX LogD: 0.74
Aromatic Rings: 3Heavy Atoms: 26QED Weighted: 0.68Np Likeness Score: -1.32

References

1.  (2018)  6-6 Fused Bicyclic Heteroaryl Compounds and their Use as LATS Inhibitors, 

Source